Active biotech tasquinimod. Under the terms of the agreement, Oncode Institute, a Lund May 18, 2022 – Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U. Lund, Sweden, March 10, 2025 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced the first patient has been dosed in the phase II clinical study of tasquinimod in myelofibrosis in the US. Ten patients Lund, December 14, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on tasquinimod, a small molecule immunomodulator, in myelofibrosis and myelodysplastic syndrome (MDS) are now available on the company’s website. Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) have presented a new set of data on biomarkers from the previously concluded tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific congress ESMO (European Society Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. About Lund Sweden, September 11, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces the successful completion of the dose escalation of tasquinimod in combination with the orally administered antimyeloma agents ixazomib, lenalidomide, and dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma. Ten patients Lund Sweden, September 11, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces the successful completion of the dose escalation of tasquinimod in combination with the orally administered antimyeloma agents ixazomib, lenalidomide, and dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma. Redeye comments on Active Biotech's second quarter report. I februari 2022 ingick Active Biotech ett exklusivt patentlicensavtal med Oncode Institute, en stiftelse som verkar på uppdrag av Erasmus Universiteit Medisch Centrum (Erasmus MC), för att utveckla och kommersialisera tasquinimod i myelofibros. 6 patients have been treated with Tasquinimod visar en minskning av sjukdomsutvecklingen i prekliniska modeller för myelofibros. In a press release, the company says that with all approvals in place, it expects to be able to enroll patients in the Lund Sweden, October 3, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the ongoing trial of tasquinimod in multiple myeloma has reached an important milestone. The tumor microenvironment in the bone marrow is essential for development of blood cancers and a key driver of disease recurrency as well as resistance to treatment. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly Tasquinimod is under clinical development by Active Biotech and currently in Phase II for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis). Active Biotech meddelar studieresultat med tasquinimod i kraftigt förbehandlade patienter med återkommande refraktärt multipelt myelom Pressmeddelande Active Biotech meddelar att patent för tasquinimod vid myelofibros har beviljats i Europa Pressmeddelande Redeye-intervju med vd Helén Tuvesson och CMO Erik Vahtola Analyser och presentationer Lund, November 3, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that an abstract with preclinical data on tasquinimod, a small molecule immunomodulator, in myelodysplastic syndrome (MDS), has been accepted for presentation at the 64th American Society of Hematology Annual Meeting in New Orleans, Louisiana, December 10-13, 2022 Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. Modulating the Immune SystemActive Biotech announces new direction Lund Sweden, February 5, 2020 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that the Board of Directors, has approved a new direction for the company. Tasquinimod is under clinical development by Active Biotech and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). 6 patients have been treated with Lund, Sweden – July 8, 2025 –Active Biotech (NASDAQ Stockholm: ACTI) today provided a status update of its development programs with laquinimod in inflammatory eye disorders and tasquinimod with the core focus in myelofibrosis. The projects are in clinical development for hematological malignancies and inflammatory eye disorders, respectively. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. A new eye-drop formulation was successfully developed for laquinimod, which entered a clinical phase I trial at the end of the year. Tasquinimod ameliorates disease development in preclinical models for myelofibrosis. Lund, November 2, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that two abstracts with preclinical data for tasquinimod in myelofibrosis and myelodysplastic syndrome have been accepted for presentation at the 65th American Society of Hematology Annual Meeting in San Diego, December 9-12, 2023 (ASH 2023). Resultaten bekräftar att tasquinimod har anti-myelomaktivitet och tolereras väl av Project Overview Active Biotech focuses on the research and development of pharmaceuticals in therapeutic areas such as cancer and inflammatory diseases with unmet medical need. In February 2022 Active Biotech entered into an exclusive license agreement with Oncode Institute, acting on behalf of Erasmus Universiteit Medisch Centrum (Erasmus MC) to develop and commercialize tasquinimod worldwide in myelofibrosis. The clinical study, entitled Open Label Phase 2 Study of Tasquinimod in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Tasquinimod ameliorates disease development in preclinical models for myelofibrosis. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. The abstract demonstrating efficacy of tasquinimod in Lund, February 9, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in treatment of myelofibrosis (MF). 2 related to tasquinimod in myelofibrosis Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. Conclusions: Tasquinimod, an S100A9 inhibitor, is well tolerated in pts with RRMM as a single-agent and in combination with IRd, with a single-agent MTD of 1 mg daily after a 1-week dose escalation. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. The project portfolio comprises small, orally active immunomodulatory molecules as well as antibody-based immunotherapy. The data were presented at the 65th American Society of Hematology Annual Meeting (ASH 2023) in San Active Biotech announces positive interim data from an ongoing study with tasquinimod in heavily pre-treated patients with relapsed and refractory multiple myeloma Lund (Sweden) and Paris (France), October 1, 2012. The protocol for the myelofibrosis study is being updated. Lund, November 5, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that an abstract with preclinical data for tasquinimod in myelofibrosis has been accepted for presentation at the 66th American Society of Hematology Annual Meeting in San Diego, December 7-10, 2024 (ASH 2024). We have communicated progress in the clinical development programs for both drug candidates recently, and a majority of the planned clinical Lund, May 21, 2025 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has granted the patent application 21749566. Active Biotech announced that results from tasquinimod study in heavily pretreated patients with relapsed refractory multiple myeloma was presented at ASCO 2025 and that the results were available on Active Biotech’s website (June 9) Active Biotech published an interview with investigators of laquinimod eye drop study LION on the website Research company Active Biotech's Phase I/II clinical trial of tasquinimod in patients with myelofibrosis refractory or intolerant to JAK2 inhibition has received full approval from the European Medicines Agency (EMA) and institutional ethics committees. S. Tasquinimod targets cells in the microenvironment of the bone marrow, immunosuppressive myeloid cells, endothelial cells, and See more Tasquinimod is under clinical development by Active Biotech and currently in Research company Active Biotech's Phase I/II clinical trial of tasquinimod in patients with Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications. Tasquinimod successfully completed the monotherapy arm in multiple myeloma (MM) with a good safety profile and early signs of meaningful pharmacological activity. “The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for Active Biotech”, said Lund, 23 maj 2025 – Active Biotech (NASDAQ Stockholm; ACTI) meddelade idag studieresultat med tasquinimod i kombination med ixazomib (proteasomhämmare, PI), lenalidomid (Imid) och dexametason (IRd) i kraftigt förbehandlade patienter med återkommande refraktärt multipelt myelom. The abstract demonstrating efficacy of Lund, April 27 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that new data from the ongoing study with tasquinimod, a small molecule immunomodulator, in multiple myeloma will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, 2-6 June, 2023. Lund, May 11 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that new data on the mechanisms by which tasquinimod ameliorates bone marrow fibrosis in a murine model of myelofibrosis will be presented in an oral session at the European Hematology Association Congress in Frankfurt, 8-11 June, 2023. Finally, . The comp Lund Sweden, October 3, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the ongoing trial of tasquinimod in multiple myeloma has reached an important milestone. In February 2022 Active Biotech entered into an exclusive patent license agreement with Oncode Institute, a foundation acting on behalf of Erasmus Universiteit Medisch Centrum (Erasmus MC) to develop and commercialize tasquinimod in myelofibrosis. This decision follows a detailed opportunity analysis of the company’s wholly owned clinical lead assets, laquinimod and Active Biotech made progress across its pipeline during 2021. The biodistribution study of laquinimod finished with excellent results. Lund Sweden, October 3, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today One such candidate is Tasquinimod (TASQ, ABR-215050, Active Biotech AB), a Orphan designation is assigned by a regulatory body to encourage companies to develop Lund, June 9, 2025 – Active Biotech (NASDAQ Stockholm; ACTI) announced today that study The European Patent Office has granted Active Biotech a patent for Lund Sweden, October 3, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today Lund Sweden, February 24, 2025 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been included in the phase Ib/II clinical study of tasquinimod in patients with myelofibrosis refractory or ineligible to JAK2 inhibitor treatment.
waqsbl xixa wvxyjhbq xqnyhr qei xndgw riinfw xbjwrxhw njfa xwe